title: Primary peritoneal serous carcinoma treated by cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. A multi-institutional study of 36 patients.
abstract: OBJECTIVE
  Primary peritoneal serous carcinoma (PPSC) is a rare condition, histologically identical to ovarian serous carcinoma and often diagnosed at late stage. There is not any standardized treatment for PPSC. A retrospective multicentric study was performed in French speaking centers to evaluate cytoreduction surgery and Hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis from different origins. The manuscript's aim was to study the particular population with PPSC.
  
  
  METHODS
  Between September 1997 and July 2007, 36 patients with PPSC from 9 institutions underwent 39 procedures.
  
  
  RESULTS
  Mortality and morbidity rates were 5.6% and 20.6% respectively. The overall survival at 1, 3 and 5 years are respectively 93.6, 71.5 and 57.4%. The median overall survival was not reached. By univariate analysis, the only factor that had prognostic value was PCI (p = 0.03).
  
  
  CONCLUSIONS
  The therapeutic approach combining cytoreductive surgery with HIPEC may achieve long-term survival in patients with PPSC.
authors.affiliation: Surgical Oncology Department, Lyon Civil Hospices, South Lyon University Hospital Center, 165 chemin du grand Revoyet, 69365 Pierre Bénite, France. naoualbakrin@chu-lyon.fr
authors.forename: N
authors.initials: N
authors.lastname: Bakrin
authors.forename: F N
authors.initials: FN
authors.lastname: Gilly
authors.forename: D
authors.initials: D
authors.lastname: Baratti
authors.forename: J M
authors.initials: JM
authors.lastname: Bereder
authors.forename: F
authors.initials: F
authors.lastname: Quenet
authors.forename: G
authors.initials: G
authors.lastname: Lorimier
authors.forename: F
authors.initials: F
authors.lastname: Mohamed
authors.forename: D
authors.initials: D
authors.lastname: Elias
authors.forename: O
authors.initials: O
authors.lastname: Glehen
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002277:Carcinoma / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D015331:Cohort Studies; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005602:France; D006801:Humans; D007036:Hypothermia, Induced / Q000379:methods; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010534:Peritoneal Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome